Amalgamated Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Amalgamated Financial’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$1.03M	Buy	+14,171	New	+$986K	0.01%	1159

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Financial's RARE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2022: 14,171 shares worth $1.03M. The stake represents 0.01% of the portfolio and ranks #1159 among its holdings.

240 funds tracked by Wall St. Rank hold RARE as of Q1 2022.

Amalgamated Financial held 14,171 shares of Ultragenyx Pharmaceutical worth $1.03M as of Q1 2022.
Ultragenyx Pharmaceutical was a new Amalgamated Financial position in Q1 2022.
Ultragenyx Pharmaceutical made up 0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1159 holding.
240 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.